PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.56%
Negative net income growth while CRWD stands at 30.05%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-18.03%
Negative yoy D&A while CRWD is 6.21%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
181.57%
Well above CRWD's 61.99% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
4.53%
Less SBC growth vs. CRWD's 13.23%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-13.53%
Both reduce yoy usage, with CRWD at -200.00%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
223.57%
AR growth while CRWD is negative at -124.34%. John Neff would note competitor possibly improving working capital while we allow AR to rise.
-142.71%
Negative yoy inventory while CRWD is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-176.36%
Negative yoy AP while CRWD is 184.01%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-63.29%
Negative yoy usage while CRWD is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
4.21%
Lower 'other non-cash' growth vs. CRWD's 14.15%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-12.19%
Both yoy CFO lines are negative, with CRWD at -13.35%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
3.61%
Lower CapEx growth vs. CRWD's 64.44%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
97.49%
Acquisition growth of 97.49% while CRWD is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
-2.61%
Negative yoy purchasing while CRWD stands at 31.64%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-16.63%
Both yoy lines are negative, with CRWD at -36.63%. Martin Whitman suspects an environment prompting fewer sales or fewer maturities within the niche.
-55.51%
Both yoy lines negative, with CRWD at -9.26%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
13.16%
Lower net investing outflow yoy vs. CRWD's 52.10%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
25.00%
Debt repayment growth of 25.00% while CRWD is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
47.95%
We slightly raise equity while CRWD is negative at -200.00%. John Neff sees competitor possibly preserving share count or buying back shares.
-146.84%
We cut yoy buybacks while CRWD is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.